Vitruvias Thyroid Tablets Recall Over Superpotent Drug

Source: FDA · United States

Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.

Vitruvias Therapeutics is recalling 1955 bottles of Thyroid Tablets, USP, 1/2 Grain (30 mg) due to superpotency.

Reading this FDA recall beyond the headline

This notice was issued by FDA on September 29, 2026 and geographically references United States. The FDA classifies this as a Class I recall, with the stated reason "Superpotent Drug", distributed us nationwide.. FDA recall classes run from I (reasonable probability of serious harm) to III (unlikely to cause harm), so the class number is the fastest way to gauge severity here. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.

A quick skim tells you whether this affects you directly; a closer read tells you more. Check the scope, the source, and how recent the record is, then weigh it against related notices rather than treating any single one as a trend.

Before acting, the primary agency source is available to check alongside this summary. Its related labels are recall, product-safety, fda, Drugs.

What Happened

Vitruvias Therapeutics Inc is conducting a voluntary recall of Thyroid Tablets, USP, 1/2 Grain (30 mg) because the product is superpotent.

Which Products Are Affected

The recall affects 1955 bottles of Thyroid Tablets, USP, 1/2 Grain (30 mg), NDC 69680-166-00, Lot # 504950 with expiration date 09/30/2026. The product is distributed nationwide in the United States.

What You Should Do

Consumers should stop using the affected product and contact Vitruvias Therapeutics for return or refund instructions.

Why This Matters

This Class I recall involves a superpotent prescription drug distributed across the United States.

Source

FDA Recall D-0866-2026

Original source: FDA Official Notice ↗

All FDA Recalls →

Comparable nationwide notices (length or severity timing) 8

Two cross-category peer sets, both computed from Areazine's own archive: notices with a similar body length, and notices near the same severity and agency date. These are drawn from other categories, not the same-feed Related list above.

Common Questions

Questions readers often have about this FDA recall.

What is this FDA recall about? ▾
Vitruvias Therapeutics is recalling 1955 bottles of Thyroid Tablets, USP, 1/2 Grain (30 mg) due to superpotency.
Which agency issued this alert? ▾
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How is this recall classified, and why does that matter? ▾
The FDA classifies this as a Class I recall, citing "Superpotent Drug" as the reason. Class I is the most serious (reasonable probability of serious harm), Class II is a moderate or temporary health risk, and Class III is unlikely to cause harm.
What area is affected? ▾
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more FDA Recalls updates? ▾
Browse the full FDA Recalls feed on Areazine at areazine.com/recalls/fda/ for the latest updates from FDA and other agencies.